Carbon monoxide–releasing molecule-3: Amelioration of renal ischemia reperfusion injury in a rat model

Purpose Despite the role of carbon monoxide in ameliorating ischemia-reperfusion injury (IRI), its use in the clinical setting is restricted owing to its toxicity. Herein, we investigated the in vivo effects of carbon monoxide–releasing molecule-3 (CORM-3) on IRI. Materials and Methods Fifteen rats were equally and randomly divided into three groups: sham (right nephrectomy), control (right nephrectomy and left renal ischemia), and CORM-3 (right nephrectomy and CORM-3 injection before left renal ischemia). Kidney tissues and blood samples collected from sacrificed rats were evaluated to determine the renoprotective effect and mechanism of CORM-3. Results Concentrations of serum creatinine and kidney injury molecule-1 in the CORM-3 group were significantly lower than in the control group after 75 minutes of IRI (1.2 vs. 2.4 mg/dL, p=0.01, and 292 vs. 550 pg/mL, p<0.001, respectively). Furthermore, the CORM-3 group exhibited a higher portion of normal tubules and glomeruli. TUNEL staining revealed fewer apoptotic renal tubular cells in the CORM-3 group than in the control group. The expression of 960 genes in the CORM-3 group was also altered. Pretreatment with CORM-3 before renal IRI produced a significant renoprotective effect. Fifteen of the altered genes were found to be involved in the peroxisome proliferator-activated receptors signaling pathway, and the difference in the expression of these genes between the CORM-3 and control groups was statistically significant (p<0.001). Conclusions CORM-3 ameliorates IRI by decreasing apoptosis and may be a novel strategy for protection against renal warm IRI.

[1]  Colin H. Wilson,et al.  Machine perfusion preservation versus static cold storage for deceased donor kidney transplantation. , 2019, The Cochrane database of systematic reviews.

[2]  M. Nicholson,et al.  Ischemia-reperfusion injury in renal transplantation: 3 key signaling pathways in tubular epithelial cells. , 2019, Kidney international.

[3]  N. Selzner,et al.  PPAR-gamma activation is associated with reduced liver ischemia-reperfusion injury and altered tissue-resident macrophages polarization in a mouse model , 2018, PloS one.

[4]  Xi Chen,et al.  The Role of Peroxisome Proliferator-Activated Receptor γ in Mediating Cardioprotection Against Ischemia/Reperfusion Injury , 2018, Journal of cardiovascular pharmacology and therapeutics.

[5]  Bo-Hwa Choi,et al.  Near-Normalized Gene Expression Profiles in Bladder With Detrusor Overactivity in Rats With Bladder Outlet Obstruction After Deobstruction , 2017, International neurourology journal.

[6]  A. Zumrutbas,et al.  The renoprotective effects of mannitol and udenafil in renal ischemia-reperfusion injury model , 2017, Investigative and clinical urology.

[7]  L. Gunaratnam,et al.  Hydrogen Sulfide Treatment Mitigates Renal Allograft Ischemia-Reperfusion Injury during Cold Storage and Improves Early Transplant Kidney Function and Survival Following Allogeneic Renal Transplantation. , 2015, The Journal of urology.

[8]  K. Lee,et al.  Renoprotective Mechanism of Remote Ischemic Preconditioning Based on Transcriptomic Analysis in a Porcine Renal Ischemia Reperfusion Injury Model , 2015, PloS one.

[9]  J. Kaouk,et al.  Minimally invasive partial nephrectomy in the age of the ‘trifecta’ , 2015, BJU international.

[10]  H. Pazoki-Toroudi,et al.  ATP-dependent potassium channels are implicated in simvastatin pretreatment-induced inhibition of apoptotic cell death after renal ischemia/reperfusion injury , 2015, Medical journal of the Islamic Republic of Iran.

[11]  S. Ryter,et al.  Carbon monoxide: present and future indications for a medical gas , 2013, The Korean journal of internal medicine.

[12]  Jie Cai,et al.  "Trifecta" in partial nephrectomy. , 2013, The Journal of urology.

[13]  G. Janetschek,et al.  Cooling mechanisms in laparoscopic partial nephrectomy: are really necessary? , 2013, Archivos españoles de urología.

[14]  A. Şener,et al.  Detrimental effects of prolonged warm renal ischaemia‐reperfusion injury are abrogated by supplemental hydrogen sulphide: an analysis using real‐time intravital microscopy and polymerase chain reaction , 2012, BJU international.

[15]  A. Shokeir,et al.  Role of combination of l‐arginine and α‐tocopherol in renal transplantation ischaemia/reperfusion injury: a randomized controlled experimental study in a rat model , 2011, BJU international.

[16]  G. Ogaya‐Pinies,et al.  Intravenous sildenafil as a preconditioning drug against hemodynamic consequences of warm ischemia-reperfusion on the kidney. , 2011, The Journal of urology.

[17]  Hao Wang,et al.  Carbon monoxide-releasing molecules protect against ischemia-reperfusion injury during kidney transplantation. , 2011, Kidney international.

[18]  L. Otterbein,et al.  Intraoperative Administration of Inhaled Carbon Monoxide Reduces Delayed Graft Function in Kidney Allografts in Swine , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  L. Otterbein,et al.  The therapeutic potential of carbon monoxide , 2010, Nature Reviews Drug Discovery.

[20]  Inderbir S Gill,et al.  Every minute counts when the renal hilum is clamped during partial nephrectomy. , 2010, European urology.

[21]  D. Stolz,et al.  Carbon Monoxide Ameliorates Renal Cold Ischemia-Reperfusion Injury With an Upregulation of Vascular Endothelial Growth Factor by Activation of Hypoxia-Inducible Factor , 2008, Transplantation.

[22]  E. Mazzon,et al.  ROLE OF ENDOGENOUS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-α (PPAR-α) LIGANDS IN THE DEVELOPMENT OF GUT ISCHEMIA AND REPERFUSION IN MICE , 2006 .

[23]  E. Mazzon,et al.  ROLE of endogenous peroxisome proliferator-activated receptor-alpha (PPAR-alpha) ligands in the development of gut ischemia and reperfusion in mice. , 2006, Shock.

[24]  G. Lopaschuk,et al.  Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. , 2006, American journal of physiology. Heart and circulatory physiology.

[25]  G. Lopaschuk,et al.  Chronic activation of PPARα is detrimental to cardiac recovery after ischemia , 2006 .

[26]  R. Foresti,et al.  Therapeutic applications of carbon monoxide-releasing molecules , 2005, Expert opinion on investigational drugs.

[27]  H. Drummond,et al.  Protective effect of carbon monoxide-releasing compounds in ischemia-induced acute renal failure. , 2005, Journal of the American Society of Nephrology : JASN.

[28]  R. Foresti,et al.  Bioactivity and pharmacological actions of carbon monoxide-releasing molecules. , 2003, Current pharmaceutical design.

[29]  N. Patel,et al.  Rosiglitazone and 15‐deoxy‐Δ12,14‐prostaglandin J2, ligands of the peroxisome proliferator‐activated receptor‐γ (PPAR‐γ), reduce ischaemia/reperfusion injury of the gut , 2003 .

[30]  W. Wahli,et al.  Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. , 2003, Gastroenterology.

[31]  N. Patel,et al.  Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. , 2003, British journal of pharmacology.